SECsense Logo

Aptevo Therapeutics Inc. 8-K Report: Key Insights on Corporate Developments

$APVO
Form 8-K
Filed on: 2025-02-11
Source
Aptevo Therapeutics Inc. 8-K Report: Key Insights on Corporate Developments

Based on the provided section of the financial report, here are the key insights and information extracted:

  1. Entity Identification:
  • Company Name: Aptevo Therapeutics Inc.
  • CIK (Central Index Key): 0001671584
  • SEC File Number: 001-37746
  • EIN (Employer Identification Number): 81-1567056
  • Address: 2401 4th Avenue, Suite 1050, Seattle, WA 98121
  • Contact Number: (206) 838-0500
  1. Filing Information:
  • Form Type: 8-K (which is a report of unscheduled material events or corporate changes)
  • Filing Date: February 11, 2025
  1. Securities Information:
  • Common Stock Par Value: $0.001
  • Stock Ticker: APVO
  • Exchange: NASDAQ
  1. Reporting Period:
  • Start Date: February 11, 2025
  • End Date: February 11, 2025
  • Filing Context: The context indicates that this filing covers the specific date of February 11, 2025, implying that it may be related to an event occurring on that day.

Insights:

  • The filing is a Form 8-K, which typically indicates that Aptevo Therapeutics Inc. is reporting a significant event that may affect the company's financial condition or operations.
  • The fact that the report is dated for the same day suggests an immediate disclosure, which could signal an urgent development, such as a major corporate announcement, acquisition, or leadership change.
  • The company is listed on NASDAQ under the ticker APVO, indicating it is publicly traded and subject to SEC regulations.
  • The par value of the common stock is relatively low, which is common for many biotech firms, especially those in early stages or undergoing significant changes.

This information is critical for investors and analysts to assess the current status and potential future performance of Aptevo Therapeutics Inc.